Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 31101761
Saint-Germain E, et al. (2019) Phosphorylation of SOCS1 Inhibits the SOCS1-p53 Tumor Suppressor Axis. Cancer Res 79, 3306-3319 31101761
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y80-p - SOCS1 (human)
Modsite: LLDACGFyWGPLSVH SwissProt Entrez-Gene
Orthologous residues
SOCS1 (human): Y80‑p, SOCS1 (mouse): Y81‑p, SOCS1 (rat): Y81‑p
Characterization
Methods used to characterize site in vivo immunoassay, immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer, B cell lymphoma, Hodgkin's lymphoma
Relevant cell lines - cell types - tissues:  B lymphocyte, IMR-90 (fibroblast), MEF (fibroblast), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
KINASE Yes (human)
KINASE LYN (human)
KINASE BLK (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF (human) increase
dasatinib decrease
saracatinib decrease
Downstream Regulation
Effect of modification (function):  activity, inhibited, intracellular localization, molecular association, regulation
Effect of modification (process):  carcinogenesis, induced, signaling pathway regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
SOCS1 (human) Induces co-immunoprecipitation
p53 (human) Disrupts transcription, inhibited functional assay, co-immunoprecipitation
Comments:  inhibits SOCS1 tumor suppressor activity; inactivates SOCS1-p53 senescence pathway; induces dimers formation
Associated Diseases
Diseases Alterations Comments
lymphoma increased

Y81-p - SOCS1 (mouse)
Modsite: LLDACGFyWGPLSVH SwissProt Entrez-Gene
Orthologous residues
SOCS1 (human): Y80‑p, SOCS1 (mouse): Y81‑p, SOCS1 (rat): Y81‑p
Characterization
Methods used to characterize site in vivo mass spectrometry (in vitro)
Disease tissue studied:  leukemia, chronic myelogenous leukemia, liver cancer
Relevant cell lines - cell types - tissues:  BV-173 (myeloid), HepG2 (hepatic), IMR-90 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  SOCS1 incubated with cell line lysates